Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0657 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | OTHER | 7mg MK0657 capsules + \>/=1.0 mg/kg/hr dose of levodopa. |
| 2 | OTHER | 7mg MK0657 Pbo capsules + \>/=1.0 mg/kg/hr dose of levodopa. |
| Name | Type | Description |
|---|---|---|
| MK0657 | DRUG | 7mg MK0657 capsules |
| Comparator: Placebo (unspecified) | DRUG | 7mg MK0657 Pbo capsules |
| Comparator: levodopa | DRUG | levodopa \>/=1.0 mg/kg/hr dose of levodopa. levodopa infusions will occur over a 2 hour period |
| Comparator: carbidopa | DRUG | carbidopa 25mg administered 3 times: at 1 hour before levodopa infusion and at 1 and 3 hours after the start of levodopa infusion. |
Inclusion Criteria: * Parkinson's Disease patients between the ages of 40 and 80 inclusive * Patient is in general good health based on screening assessments * Patient is willing to discontinue anti-parkinson's medications at least 8 hours prior to dosing * Patient is levodopa responsive with levod...
MK0657 is an investigational small molecule being studied for the treatment of Parkinson's Disease. It is in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being developed by Merck & Company, Inc. for use in patients with this neurological condition.
MK0657 is a small molecule being developed for Parkinson's Disease, but its specific molecular target has not been disclosed. The drug is in Phase 1 clinical trials, and the mechanism of action has not been publicly detailed. Merck & Company, Inc. is investigating its potential in this neurological indication.
MK0657 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in Phase 1 clinical development for the treatment of Parkinson's Disease.
MK0657 is in Phase 1 clinical development. It is an investigational drug for Parkinson's Disease and has not been approved by the FDA or other regulatory agencies. The drug is still in the early stages of clinical testing, with one Phase 1 trial completed.
MK0657 has one completed Phase 1 clinical trial, identified as NCT00505843, titled "A Study of MK0657 in Parkinson's Disease Patients (0657-006)." This randomized, double-blind, controlled study enrolled 18 participants aged 40 years and older with Parkinson's Disease.
MK0657 is the investigational name for this drug candidate being developed by Merck & Company, Inc. for Parkinson's Disease. No alternative names have been reported for this compound in the available clinical trial information. It is currently in Phase 1 development.